Technical Analysis for DXCM - DexCom, Inc.
|Grade||Last Price||% Change||Price Change|
DXCM closed up 1.67 percent on Thursday, January 17, 2019, on 52 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
|Weak or Absent||Up||Up||Up|
|See historical DXCM trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 17||New 52 Week Closing High||Bullish||0.00%|
|Jan 17||Multiple of Ten Bearish||Other||0.00%|
|Jan 17||Wide Bands||Range Expansion||0.00%|
|Jan 17||Overbought Stochastic||Strength||0.00%|
|Jan 16||Wide Bands||Range Expansion||1.67%|
|Jan 16||Overbought Stochastic||Strength||1.67%|
|Jan 15||Stochastic Sell Signal||Bearish||1.67%|
|Jan 15||Pocket Pivot||Bullish Swing Setup||1.67%|
|Jan 15||Upper Bollinger Band Walk||Strength||1.67%|
|Jan 15||Wide Bands||Range Expansion||1.67%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. Its ambulatory product line includes SEVEN PLUS, DexCom G4 system, and DexCom G4 PLATINUM system for adults with diabetes to detect trends and track glucose patterns, to aid in the detection of hypoglycemia and hyperglycemia, and to facilitate acute and long-term therapy adjustments. The company's in-hospital product line comprises GlucoClear, a blood-based in-vivo automated glucose monitoring system for use by healthcare providers in the hospital. It also offers SweetSpot, a software platform that enables patients to aggregate and analyze data from diabetes devices and to share it with their healthcare providers. The company markets its products directly to endocrinologists, physicians, and diabetes educators primarily in the United States. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more DXCM news...
|52 Week High||152.14|
|52 Week Low||52.92|
|200-Day Moving Average||113.4855|
|50-Day Moving Average||128.1748|
|20-Day Moving Average||126.278|
|10-Day Moving Average||138.58|
|Average True Range||5.8887|
|Chandelier Exit (Long, 3 ATRs )||133.3139|
|Chandelier Exit (Short, 3 ATRs )||122.7161|
|Upper Bollinger Band||154.9486|
|Lower Bollinger Band||97.6074|
|Percent B (%b)||0.9|
|MACD Signal Line||3.2321|
|Market Cap||12.95 Billion|
|Num Shares||86.6 Million|
|Price-to-Earnings (P/E) Ratio||-196.71|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||156.03|
|Resistance 3 (R3)||155.79||153.39||154.94|
|Resistance 2 (R2)||153.39||151.72||153.50||154.57|
|Resistance 1 (R1)||151.44||150.70||152.42||151.68||154.21|
|Support 1 (S1)||147.09||147.37||148.07||147.33||144.79|
|Support 2 (S2)||144.69||146.35||144.80||144.43|
|Support 3 (S3)||142.74||144.69||144.06|
|Support 4 (S4)||142.98|